In the large CANTOS trial of 10,061 patients with previous myocardial infarction and elevated CRP (> 2 mg/L), canakinumab, a monoclonal antibody blocking interleukin-1β, led to a 15% significantly lower rate of atherothrombotic events [27], a 36% reduction in need for coronary revascularization [27], and a dose-dependent reduction in hospitalization for heart failure [28]. The gene discussed is CRP; the disease is myocardial infarction.